2025.02.07
*Notice* UBE Corporation and UBE Corporation Commence Joint Research on Novel Combination Cancer Immunotherapy
We are pleased to announce that Dr. Hiroaki Nagano (Division of Advanced Cell Therapy) and UBE Corporation have started a joint research on a novel combined cancer immunotherapy to enhance the therapeutic efficacy of immune checkpoint inhibitors (1) for gastrointestinal cancer. The joint research aims to establish a strategy to induce the immune environment (tumor microenvironment) around cancer cells to an “immunologically hot state (2)” and to improve efficacy in a broader patient population.
1 Immune checkpoint inhibitor: A drug that releases the brake that immune cells receive from cancer cells.
2 Immunologically Hot state: A state in which immune cells are actively working inside the tumor, facilitating effective attack on cancer cells.
A press release has been posted on the University’s website.
For details, please click the following link.
https://www.yamaguchi-u.ac.jp/wp-content/uploads/2025/02/25020501.pdf